Experience with the use of strontium ranelate in men with bronchial asthma in combination with osteoporosis

Ivchenkova A. F., Mutalova E. G.

to study the efficacy of strontium ranelate on the impact of bone mineral density (BMD), biochemical markers of bone turnover, pain, daily activity and to assess tolerability in men with bronchial asthma (BA) in combination with osteoporosis (OP). Results. The average age of patients with BA in combination with OP was 64.6±1.2 years; the duration of BA was 20.1±9.8 years. Patients with BA in combination with OP received basiс therapy of BA, strontium ranelate, calcium and vitamin D. For the 12 months of treatment was significant increase in BMD in the lumbar spine by 6.6% and femoral neck by 1.9%. The level of bone resorption marker (β-cross laps) during therapy decreased compared to baseline by 37.7 % (p < 0.0001), and the level of marker of bone formation (total P1NP) was increased by 51.4 % (p < 0.0001).

Keywords:bronchial asthma, osteoporosis, strontium ranelate, bone mineral density, biochemical markers of bone turnover